Amicus Therapeutics, Inc. (FOLD) Short Interest Down 23.0% in January

Share on StockTwits

Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 22,063,910 shares, a drop of 23.0% from the January 15th total of 28,648,935 shares. Approximately 12.0% of the shares of the company are sold short. Based on an average daily trading volume, of 2,934,535 shares, the short-interest ratio is currently 7.5 days.

In other Amicus Therapeutics news, insider Hung Do sold 53,269 shares of the stock in a transaction on Wednesday, January 16th. The stock was sold at an average price of $12.03, for a total value of $640,826.07. Following the sale, the insider now directly owns 452,713 shares of the company’s stock, valued at $5,446,137.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John F. Crowley sold 103,500 shares of the stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $11.71, for a total value of $1,211,985.00. Following the completion of the sale, the chief executive officer now directly owns 771,581 shares in the company, valued at $9,035,213.51. The disclosure for this sale can be found here. Insiders sold 212,769 shares of company stock worth $2,520,371 over the last ninety days. 2.90% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC increased its holdings in shares of Amicus Therapeutics by 3.3% during the third quarter. Perceptive Advisors LLC now owns 20,694,424 shares of the biopharmaceutical company’s stock valued at $250,196,000 after purchasing an additional 670,000 shares during the period. Vanguard Group Inc. grew its holdings in Amicus Therapeutics by 3.3% during the third quarter. Vanguard Group Inc. now owns 16,807,772 shares of the biopharmaceutical company’s stock worth $203,205,000 after acquiring an additional 541,308 shares during the period. Vanguard Group Inc grew its holdings in Amicus Therapeutics by 3.3% during the third quarter. Vanguard Group Inc now owns 16,807,772 shares of the biopharmaceutical company’s stock worth $203,205,000 after acquiring an additional 541,308 shares during the period. BlackRock Inc. grew its holdings in Amicus Therapeutics by 0.9% during the fourth quarter. BlackRock Inc. now owns 16,521,820 shares of the biopharmaceutical company’s stock worth $158,279,000 after acquiring an additional 147,484 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Amicus Therapeutics by 7.7% during the third quarter. Janus Henderson Group PLC now owns 8,806,359 shares of the biopharmaceutical company’s stock worth $106,469,000 after acquiring an additional 627,972 shares during the period.

Several equities research analysts have weighed in on FOLD shares. Guggenheim started coverage on Amicus Therapeutics in a research report on Monday, December 17th. They issued a “buy” rating and a $18.00 target price on the stock. Citigroup raised Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $12.59 target price on the stock in a research report on Wednesday, January 16th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, February 5th. BidaskClub lowered Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, October 26th. Finally, ValuEngine lowered Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Amicus Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $18.60.

Shares of FOLD opened at $10.97 on Tuesday. The firm has a market cap of $2.12 billion, a PE ratio of -3.76 and a beta of 1.77. The company has a current ratio of 9.12, a quick ratio of 9.03 and a debt-to-equity ratio of 0.78. Amicus Therapeutics has a one year low of $8.27 and a one year high of $17.62.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://weekherald.com/2019/02/12/amicus-therapeutics-inc-fold-short-interest-down-23-0-in-january.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Read More: What are defining characteristics of a correction?

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply